CTMX - CytomX Therapeutics, Inc.
26.08 0.00 (0.00%)
After hours: 4:53PM EDT
| Previous Close | 26.57 |
| Open | 26.59 |
| Bid | 25.00 x 100 |
| Ask | 27.50 x 100 |
| Day's Range | 25.62 - 26.70 |
| 52 Week Range | 13.00 - 35.00 |
| Volume | 266,971 |
| Avg. Volume | 375,250 |
| Market Cap | 1.007B |
| Beta | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings Date | May 3, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.29 |
- ACCESSWIRE•last month
Blog Exposure - Bellicum Reported Encouraging Interim Data in Pediatric AML Patients Treated with BPX-501
Stock Monitor: CytomX Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on Bellicum Pharma, Inc. (NASDAQ: BLCM ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CTMX earnings conference call or presentation 7-Mar-18 10:00pm GMT
Q4 2017 CytomX Therapeutics Inc Earnings Call
- Associated Press•2 months ago
CytomX Therapeutics beats Street 4Q forecasts
On a per-share basis, the South San Francisco, California-based company said it had profit of 2 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- GlobeNewswire•2 months ago
CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
SOUTH SAN FRANCISCO, Calif., March 07, 2018-- CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today reported ...
- ACCESSWIRE•2 months ago
CytomX Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / CytomX Therapeutics, Inc. (NASDAQ: CTMX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 5:00 PM Eastern ...
- Simply Wall St.•2 months ago
What Does CytomX Therapeutics Inc’s (NASDAQ:CTMX) Past Performance Indicative Of Its Future?
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
- GlobeNewswire•2 months ago
CytomX to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 01, 2018-- CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the ...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress ...
- GlobeNewswire•2 months ago
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2018-- CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to ...
Market Realist•3 months agoA Look into Amgen’s Collaborations in 2H17
How Is Amgen Positioned for 2018?
- Zacks•5 months ago
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
Capital Cube•5 months agoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
Categories: Yahoo FinanceGet free summary analysis CytomX Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 24.14 million, Net Earnings of USD -10.25 million. Change in operating cash flow of 59.54% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)
- Capital Cube•5 months ago
ETFs with exposure to CytomX Therapeutics, Inc. : November 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytomX Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CTMX-US. Comparing the performance and risk of CytomX Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Associated Press•6 months ago
CytomX Therapeutics reports 3Q loss
The South San Francisco, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- Marketwired•6 months ago
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
CytomX Therapeutics, Inc. , a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today reported third quarter 2017 financial results.
- Zacks•6 months ago
Cancer Space Last Week Update: Pipeline Expansion in Focus
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
